scholarly article | Q13442814 |
P356 | DOI | 10.1074/JBC.M708607200 |
P698 | PubMed publication ID | 18165682 |
P50 | author | Tohru Natsume | Q56332455 |
P2093 | author name string | Shun-ichiro Iemura | |
Hayley Spearman | |||
David Beeson | |||
Kumiko Okada | |||
Osamu Higuchi | |||
Yuji Yamanashi | |||
Makiko Ueno | |||
Johko Hamuro | |||
P2860 | cites work | Sleuthing molecular targets for neurological diseases at the neuromuscular junction | Q35120131 |
Myasthenic syndrome caused by mutation of the SCN4A sodium channel | Q35163768 | ||
The therapy of congenital myasthenic syndromes | Q36774720 | ||
Dok-7 mutations underlie a neuromuscular junction synaptopathy | Q40242364 | ||
Regulation of C2C12 myogenic terminal differentiation by MKK3/p38alpha pathway | Q40688494 | ||
Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. | Q42498797 | ||
MUSK, a new target for mutations causing congenital myasthenic syndrome | Q45116927 | ||
Drosophila Dok is required for embryonic dorsal closure | Q46843792 | ||
Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes | Q48199451 | ||
Light on limb-girdle myasthenia | Q48461858 | ||
126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. | Q53272034 | ||
Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit | Q24306667 | ||
Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins | Q24312189 | ||
p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells | Q24315152 | ||
A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome | Q24317127 | ||
Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity | Q24319151 | ||
Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic) | Q24539214 | ||
Characterization of a novel member of the DOK family that binds and modulates Abl signaling | Q24554382 | ||
Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans | Q24612220 | ||
Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome | Q24613679 | ||
Mutations in the embryonal subunit of the acetylcholine receptor (CHRNG) cause lethal and Escobar variants of multiple pterygium syndrome | Q24669597 | ||
Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit | Q24669721 | ||
Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation | Q24685580 | ||
The muscle protein Dok-7 is essential for neuromuscular synaptogenesis | Q28247970 | ||
Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth | Q28274931 | ||
Clinical features of the DOK7 neuromuscular junction synaptopathy | Q28298999 | ||
Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok | Q28302094 | ||
CrkII induces serum response factor activation and cellular transformation through its function in Rho activation | Q30164525 | ||
Congenital myasthenic syndrome caused by low-expressor fast-channel AChR delta subunit mutation | Q34166823 | ||
Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems | Q34292599 | ||
Autoimmune channelopathies and related neurological disorders | Q34571467 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | congenital disorder | Q727096 |
P1104 | number of pages | 7 | |
P304 | page(s) | 5518-5524 | |
P577 | publication date | 2007-12-29 | |
P1433 | published in | Journal of Biological Chemistry | Q867727 |
P1476 | title | Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7 | |
P478 | volume | 283 |
Q34551830 | A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia. |
Q37985524 | Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment |
Q28509926 | ColQ controls postsynaptic differentiation at the neuromuscular junction |
Q27013130 | Crosstalk between Agrin and Wnt signaling pathways in development of vertebrate neuromuscular junction |
Q37795116 | Docking proteins. |
Q38346538 | Dok-7 promotes slow muscle integrity as well as neuromuscular junction formation in a zebrafish model of congenital myasthenic syndromes |
Q34244283 | Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L |
Q40190415 | Dok-7/MuSK signaling and a congenital myasthenic syndrome. |
Q33611140 | Downstream of tyrosine kinase/docking protein 6, as a novel substrate of tropomyosin-related kinase C receptor, is involved in neurotrophin 3-mediated neurite outgrowth in mouse cortex neurons |
Q34114589 | Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7 |
Q46540917 | Examination of transcript amounts and activity of protein kinase CK2 in muscle lysates of different types of human muscle pathologies |
Q50131806 | Fundamental Molecules and Mechanisms for Forming and Maintaining Neuromuscular Synapses. |
Q34345625 | LRP4 is critical for neuromuscular junction maintenance |
Q37409458 | MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. |
Q36085849 | Multiscale Simulations Suggest a Mechanism for the Association of the Dok7 PH Domain with PIP-Containing Membranes |
Q42186779 | Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction |
Q43220535 | Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. |
Q40793178 | Postnatal knockdown of dok-7 gene expression in mice causes structural defects in neuromuscular synapses and myasthenic pathology |
Q42109837 | Protein kinase CK2 interacts at the neuromuscular synapse with Rapsyn, Rac1, 14-3-3γ, and Dok-7 proteins and phosphorylates the latter two. |
Q36480886 | Sorbs1 and -2 Interact with CrkL and Are Required for Acetylcholine Receptor Cluster Formation |
Q38062321 | Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation. |
Q38757489 | Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer |
Q34581104 | The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses |
Q55236647 | The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. |
Q51052741 | The carboxyl-terminal region of Dok-7 plays a key, but not essential, role in activation of muscle-specific receptor kinase MuSK and neuromuscular synapse formation. |
Q24337679 | The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization |
Q33674551 | The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer |
Q39337788 | The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome |